For commercial accounts, this cell line is only distributed under the terms of a fully signed and executed ATCC® Material Transfer Agreement and Addendum. If the commercial account is screening per completed Addendum, the recipient will be required to pay a Screening Fee (ATCC® ACS-2103™) of $4000.00.
Screening Use is defined as use of Biological Material in small molecule and biologic drug discovery, including initial target identification and validation, assay development, high throughput screening, hit identification, lead optimization, and selection of candidates for clinical development.
If the commercial account is not screening per the completed Addendum, the recipient will not be required to pay a Screening Fee.
In addition to the foregoing, this product's use is governed by a Limited License. For information on purchasing a license to use this product for purposes other than those permitted in the Label License, please contact Promega.
In addition to the foregoing, any proposed commercial use of ATCC® CRL-4049 NFκB-TIME must also be negotiated with University of California, San Francisco, Office of Technology Management, 3333 California Street, Suite S-11, San Francisco, CA 94143-1209, Tel: 415.502.1585, Fax: 415.502.1661.